When people hear the word “psychedelics,” their minds often jump to the counterculture movements of the 1960s or current debates surrounding recreational legalization. This often leads to the question: “Isn’t APP just trying to open the door to legalizing LSD?”
The answer is a definitive no.
The Association for Prescription Psychedelics (APP) is focused exclusively on FDA-approved and DEA-rescheduled prescription psychedelic medicines. We are not advocates for a lifestyle or a cultural movement; we are advocates for patients who have run out of options and a medical system that is currently failing them.
Our mission is built on the foundation of safety, science, and strict regulatory oversight. Unlike “decriminalization” or “legalization” models, the medical model we support ensures:
- Professional Supervision: These therapies are administered by licensed and highly trained healthcare professionals in structured clinical settings.
- Standardized Dosing: Patients receive precise, pharmaceutical-grade medicine, not unregulated substances.
- Rigorous Screening: Physicians can screen out individuals who may have contraindications, ensuring that those at risk for certain mental health issues do not receive the therapy.
- Insurance Accessibility: FDA approval is the only appropriate mechanism to ensure these treatments are reimbursed by health insurance, making them affordable for the average American.
While the debate over legalization often garners headlines, it distracts from a far more urgent reality: America’s mental health standard of care is not keeping pace with the growing crisis.
For many, the current options simply aren’t enough. Consider the innovation gap that is leaving millions behind:
- A Lost Generation of Innovation: There has been no significant innovation in PTSD medication since the early 1990s.
- Treatment Failure: 70% of people with depression do not achieve full remission with first-line SSRI or SNRI treatments.
- Unmet Needs for Anxiety: It has been 18 years since the FDA last approved a new treatment for Generalized Anxiety Disorder.
The refusal to explore new, regulated medical tools has a human and economic price. Mental illness costs the United States $282 billion every year. More importantly, we are losing one fellow American to suicide every 11 minutes.
At APP, we aren’t interested in “opening doors” to recreational drugs. We are interested in opening the doors of clinics to the 50 million Americans who are currently suffering. By focusing on FDA-regulated pathways, we can ensure that breakthrough therapies—like MDMA and psilocybin—are delivered with the safety, certainty, and clinical authority that patients and veterans deserve.
